TopFunds

Baxter International

NYSE: BAX

Stock price

26.29 USD

(+0%) TODAY

Health Care EquipmentMedical - Instruments & Supplies

Financial Performance

Share

5Y price score: (90)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: (25.9)%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    15.7

    52-week range

    30.0

    26.29

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    5 %

    Dividend Yield TTM

    0.8 %

    Market cap $

    $ 13,592

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    (12.9)

    Price / Book TTM

    2.2

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    (0.4)

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    9.2 %

    (57.7) %

    (25.9) %

    Free cash flow per share growth

    (53.3) %

    (71.9) %

    (59.8) %

    Earnings per share growth

    33.3 %

    (182.2) %

    (199.4) %

    Founded: 1,931

    Employees: 38,000

    Business Summary:Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    2026 Q2 (Jul 30, 2026)

    1) Strategic Focus and Leadership Updates
    - Baxter's leadership emphasizes a turnaround strategy, focusing on execution and operational improvements across all segments.
    - The company is consolidating its Pharmaceuticals and Infusion Therapies & Technologies businesses under a new division, Infusion Therapies & Platforms (ITP), to enhance coordination and innovation.
    - The Baxter Growth & Performance System (GPS) is being embedded into the company culture, with over 400 continuous improvement events completed in the first half of the year.

    2) Financial Performance and Segment Results
    - Q2 2026 global sales reached approximately $3 billion, reflecting a 5% increase both reported and organically.
    - Adjusted earnings per share (EPS) were $0.56, down from $0.59 YoY, impacted by mechanical headwinds but benefitting from a $75 million tariff refund contributing $0.11 per share.
    - Key segment performances:
    | Segment | Q2 Sales (in millions) | Organic Growth (%) | |-------------------------------|------------------------|--------------------| | Medical Products & Therapy | $2,100 | 5 | | Infusion Therapies & Platforms | $1,700 | 4 | | Advanced Surgery | $331 | 12 | | Healthcare Systems & Technologies | $801 | 4 |

    3) Challenges and Headwinds
    - Ongoing supply chain challenges, particularly with contract manufacturers affecting the injectables and anesthesia segments.
    - The Novum IQ LVP product remains under regulatory scrutiny, with no material impact from returns observed in Q2, but uncertainty persists regarding its market re-entry.
    - The company faces inflationary pressures and tariff impacts, with expectations of approximately $40 million in tariff-related costs in the second half of the year.

    4) Operational and Product Development Plans
    - Continued investment in innovation, including the launch of PeerVue, a digital benchmarking application, and the Vest APX Acute Care device, which has received positive initial feedback.
    - Strong demand is noted for the Connex 360 connected patient monitoring platform and the Dynamo smart hospital stretcher, with expansion into international markets.
    - The company aims to improve supply reliability and operational efficiency, particularly in the pharmaceutical portfolio.

    5) Guidance and Outlook
    - Baxter raised its full-year organic sales growth outlook to 2% to 3% and adjusted EPS guidance to $1.95 to $2.15 per diluted share, reflecting confidence in the second half of the year.
    - The company expects to achieve a net leverage target of approximately 3x by year-end, which would enhance its financial flexibility for potential M&A and capital returns.
    - The transcript lacks specific details on the anticipated impact of regulatory changes and macroeconomic factors on future performance.

    Bottom line: Baxter's Q2 results show solid progress in its turnaround strategy, with strong organic growth and operational improvements. However, ongoing challenges in supply chain and regulatory compliance remain. The raised guidance reflects confidence in continued momentum, positioning the company for sustainable growth and shareholder value creation.

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Baxter International — Financial Overview, Stock Price, Market Cap

    Baxter International is a company. Founded in 1931. As of August 26, 2026, the company's market capitalization is $13591824630 with a current stock price of $26.29.